Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...

Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted left ventricular assist ... conditions requiring life-long anticoagulation therapy as well ...

Dr. Ferguson will lead the late-stage clinical development of tecarfarin to include the pivotal trial in LVAD patients and ... conditions requiring life-long anticoagulation therapy as well ...

Cadrenal Therapeutics (CVKD) announced a leadership transition appointing James Ferguson as its new chief medical officer, effective ...

Mechanical VAD complications can arise for a number of reasons. The position and size of the implanted components, especially the cannulas, can be problematic, as can suboptimal anticoagulation ...

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

Cadrenal Therapeutics, a biopharmaceutical company listed on the Nasdaq under the ticker symbol CVKD, made a public announcement of leadership changes through an 8-K SEC filing on February 4, 2025.

PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a biopharmaceutical company specializing in cardiovascular therapies with a market capitalization of $35.2 million and impressive 210% ...

While anticoagulation is well-supported in patients ... on the use of rivaroxaban in patients with heart failure and left ventricular thrombus indicated that while rivaroxaban may improve outcomes ...

Heightened interest in left ventricular thrombus (LVT ... For patients with AMI involving anteroapical akinesis/dyskinesis, prophylactic anticoagulation may be initiated for 1–3 months, if the risk of ...